Future studies should delineate how CD36 interfaces with subtype‐defining pathways and explore whether its tumor‐suppressive effects in TNBC involve mechanisms beyond lipid metabolism, such as immune modulation or anoikis resistance. The gene discussed is CD36; the disease is neoplasm.